tebnow← All categories
Category

Pharma & Medications

813 articles indexed

CVS Caremark Settles with FTC, Promises Changes to Insulin Pricing Practices

CVS Health's Caremark has reached a significant settlement with the Federal Trade Commission (FTC) that mandates substantial changes to its pharmacy benefit management practices. This agreement, announced on Tuesday, addresses allegations that Caremark favored higher-priced insulin options to maximize rebates, consequently inflating costs for patients reliant on this essential diabetes medication. The FTC's lawsuit, filed in 2024, also targeted other major pharmacy benefit managers (PBMs) like Express Scripts and Optum Rx, with Express Scripts having already settled earlier this year. Under the terms of the settlement, Caremark is required to prioritize lower-cost medications on its formularies and ensure that savings negotiated with drug manufacturers are passed directly to clients. This includes a provision that allows patients' purchases through TrumpRx, an online drug marketplace, to count towards their deductibles in certain health plans once regulatory changes permit. Additionally, the settlement introduces measures aimed at enhancing transparency and preventing Caremark from obstructing independent pharmacies from collaborating with competing pharmacy hubs. FTC Chairman Andrew Ferguson emphasized that this settlement could lead to billions in savings for consumers facing high prescription drug prices, estimating a total of up to $8.5 billion in savings over the next decade. The reforms are particularly crucial as Caremark, along with Express Scripts and Optum Rx, controls approximately 80% of the U.S. prescription market, meaning changes in their practices could significantly impact patient costs and access to medications. Despite the anticipated benefits for consumers, the settlement does not impose financial penalties on Caremark, and analysts suggest that the PBMs may not see a decrease in profits. Instead, the settlements could help these companies avoid more severe regulatory actions in the future. CVS has expressed that this agreement allows them to focus on enhancing value for consumers and employers while promoting affordability and transparency in healthcare delivery.

BioPharma Dive/1d ago

CVS Health / FTC / pharmacy benefit managers / insulin pricing / healthcare reform

Cayman Court Orders Change in Leadership at Apple Tree Partners Amid Ongoing Bankruptcy Proceedings

A recent ruling from a Cayman Islands court has mandated that Seth Harrison, the general partner of Apple Tree Partners (ATP), relinquish control of the biotechnology venture capital firm. This decision comes amidst a complex legal battle involving ATP and its primary funders, Rigmora Biotech Investors, linked to Russian billionaire Dmitry Rybolovlev. The court's ruling could lead to the appointment of independent directors, Alexander Lawson and Barry Lynch, to oversee the fund's management. This development is significant as it follows a year of litigation, including a bankruptcy filing by ATP aimed at restructuring its operations to continue supporting its portfolio companies. The legal disputes began when Rigmora accused ATP of mismanagement and failing to meet capital commitments, while ATP countered with claims against Rigmora for withholding funds. A Delaware Chancery Court previously sided with ATP, ordering Rigmora to pay approximately $97 million to support ATP's startups. However, the Cayman Islands court's decision to potentially replace Harrison raises questions about the future direction of ATP, which has been managing around $3.6 billion in assets but is currently facing debts of approximately $216 million. As the bankruptcy proceedings continue in the U.S., where Harrison has proposed a plan to fund ATP's startups, the implications of the Cayman ruling remain uncertain. Rigmora has expressed support for the court's decision, believing that new independent oversight will enhance the fund's value. However, the U.S. bankruptcy court has yet to recognize the Cayman ruling, maintaining its authority to determine ATP's restructuring plan. The outcome of these proceedings will be closely watched by stakeholders in the biotech investment community, as it could set precedents for governance and financial management in venture capital firms.

BioPharma Dive · 1d ago

Avere Therapeutics Advances Long-Acting Psoriasis Pill Amid Reverse Merger Plans

Avere Therapeutics, an immunology-focused drug developer, is set to go public through a reverse merger with NextCure, aiming to advance its experimental oral psoriasis medication, AVR-001. This move comes with a significant financial boost of $320 million from a share and convertible note sale, led by Fairmount and Hansoh Pharma. The drug, licensed from Hansoh, is designed to compete with existing treatments like AbbVie’s Skyrizi and Johnson & Johnson’s Icotyde, offering a less frequent dosing schedule that could enhance patient adherence. The leadership team from Akero Therapeutics, which recently underwent a $4.7 billion acquisition by Novo Nordisk, will guide Avere through this transition. The merger is expected to close in the second half of 2026, after which the combined entity will trade on the Nasdaq under the ticker symbol “AVRX.” Avere's licensing agreement includes an upfront payment of $120 million and potential milestone payments totaling up to $2.18 billion, contingent on the drug's market success. Avere is currently preparing to initiate Phase 2 testing for AVR-001 in the U.S. and has plans for a global Phase 3 trial, alongside a Phase 2b trial for ulcerative colitis. Meanwhile, Hansoh is conducting a Phase 2b trial in China, with results anticipated in 2027. The competitive landscape for IL-23 inhibitors is intensifying, with Avere positioning itself to deliver a once-weekly oral therapy that promises both convenience and efficacy, as highlighted by CEO Andrew Cheng. This strategic development is crucial as the market for psoriasis treatments continues to evolve, with a growing emphasis on patient-friendly dosing regimens.

BioPharma Dive · 1d ago

Draig Therapeutics Secures $65M to Advance Brain Drug Trials for Major Depressive Disorder

Draig Therapeutics has successfully raised $65 million in a Series B funding round, aimed at advancing the development of its experimental drugs targeting psychiatric disorders, particularly major depressive disorder (MDD). This funding round, announced on July 14, 2026, was led by Deep Track Capital and included participation from Janus Henderson Investors and Marshall Wace. The financial boost will facilitate mid-stage trials for Draig's lead candidate, DT-101, which aims to restore chemical balance in the brain by targeting AMPA receptors, a promising area in the treatment of depression. The significance of this funding lies in Draig's ambition to address the challenges of psychiatric drug development, an area historically fraught with high failure rates. However, recent successes in the field have sparked renewed interest and investment in psychiatric therapies, positioning Draig to leverage this momentum. CEO Ivana Magovčević-Liebisch expressed confidence in the potential of DT-101, describing it as having 'best-in-disease potential' based on early data. Currently, Draig is conducting a global Phase 2 study of DT-101 as a standalone treatment, alongside a U.S. trial evaluating its efficacy as an adjunct therapy. In addition to DT-101, the company has two other drug candidates targeting GABA-A receptors, although details on their specific applications remain undisclosed. The recent funding will not only expedite the progress of DT-101 but also support Draig's broader research initiatives, ensuring the company remains on track to meet its near-term milestones.

BioPharma Dive · 1d ago

Agenus Shifts Focus in Colorectal Cancer Research; Oxford Advances Ebola Vaccine

Agenus has announced a strategic pivot in its clinical development approach, opting to discontinue financial support for a late-stage trial of its cancer immunotherapy combination, BOT+BAL, in late-line colorectal cancer. Instead, the company will redirect its resources towards a neoadjuvant study in specific colon cancer cases, which it estimates could represent an annual market opportunity exceeding $7 billion. This decision follows a successful $340 million funding round led by RA Capital Management and TCGX, which has resulted in a significant surge in Agenus' stock price, doubling in early trading on the announcement. In parallel, the University of Oxford has made strides in infectious disease prevention with the development of the ChAdOx1 BDBV vaccine, the first preventive shot for the Bundibugyo ebolavirus to enter Phase 1 testing. This vaccine was created in response to recent outbreaks in the Democratic Republic of the Congo and Uganda and is part of a fast-tracked initiative by the Coalition for Epidemic Preparedness Innovation (CEPI). Recruitment for the study is currently underway, with vaccinations anticipated to commence shortly. Additionally, Apnimed is preparing for an initial public offering to support the launch of its sleep apnea treatment, Oxnimbi, which has shown promise in Phase 3 trials. However, the FDA has indicated that further analyses may be necessary to demonstrate its clinical benefits. Meanwhile, Bristol Myers Squibb is awaiting FDA approval for its new multiple myeloma drug, mezigdomide, with a decision expected by May 2027. The FDA has also expanded the use of Padcev, an antibody-drug conjugate developed by Pfizer and Astellas Pharma, to include a broader patient population in early muscle-invasive bladder cancer, marking a significant advancement in treatment options for this condition.

BioPharma Dive · 2d ago

Biotech Funding Surges Amid VC Rebound, Yet Early-Stage Investment Faces Challenges

In the first half of 2026, biotechnology venture capital funding reached over $9.1 billion, marking the highest total since early 2022. This surge is attributed to strong public market performance and increased deal-making activity, with 68 biotech companies benefiting from significant investments. Notably, 76% of the funds raised were through 'megarounds' of $100 million or more, indicating a trend towards larger financing rounds. The initial public offerings (IPOs) have also contributed to this momentum, with 13 firms raising a combined $4.5 billion, showcasing a median haul of nearly $302 million. Despite this positive trend, concerns loom over the future of early-stage biotech funding. The venture capital landscape has shifted, with a notable decline in seed funding for startups, particularly those led by first-time founders. Approximately two-thirds of the venture rounds in the first half of 2026 were allocated to companies with drug prospects already in human testing, raising questions about the pipeline for future innovations. Experts warn that cuts to basic research funding at the NIH could have long-term implications for the U.S. drug industry, potentially stifling the next wave of early innovation. Moreover, the funding landscape is increasingly favoring companies with established drug prospects, often sourced from international markets, which has sparked national security concerns. While immune and cancer-focused drugmakers accounted for over 40% of funding rounds, cellular and genetic medicine developers continue to struggle, on track to raise only about $2 billion in 2026. The cautious approach of investors, influenced by regulatory scrutiny and market performance of certain treatments, suggests a more discerning investment climate moving forward.

BioPharma Dive · 2d ago

Exploring Clinical Supply Chains: Insights from Almac's New Podcast Series

Almac Clinical Services has launched a six-part podcast series titled 'From Protocol to Patient,' which delves into the complexities of clinical trial supply chains. The series aims to shed light on the extensive planning and coordination required to ensure that investigational medicines are delivered to patients safely and on time. Each episode focuses on different aspects of the supply chain, starting with the initial conversations between sponsors and clinical supply partners, which are crucial for translating scientific protocols into actionable plans. The podcast highlights the importance of defining trial needs and developing effective supply strategies early in the process. By addressing these foundational elements, biopharma companies can avoid costly delays and ensure smoother execution of clinical trials. This is particularly relevant as the industry faces increasing pressure to bring scientific breakthroughs from the lab to the market efficiently. Healthcare professionals, researchers, and industry stakeholders are encouraged to listen to the series to gain insights into the operational challenges and solutions in clinical supply management. The first episode, 'Turning Protocols into Plans,' is now available, setting the stage for subsequent discussions on packaging, distribution, and regulatory compliance. As the podcast progresses, it will provide valuable information on best practices and innovative approaches in the clinical supply chain, ultimately benefiting patients awaiting new therapies. The series represents a significant effort to enhance understanding and collaboration within the biopharma sector, ensuring that advancements in medicine reach those in need without unnecessary delays.

BioPharma Dive · 3d ago

FDA Proposes Streamlined Registration for Distributed Drug Manufacturing

On July 10, 2026, the U.S. Food and Drug Administration (FDA) announced a proposed rule aimed at modernizing the registration process for distributed drug manufacturing establishments. This initiative seeks to streamline the registration for manufacturers operating under a 'hub-and-spoke' model, allowing them to register as a single entity rather than requiring each unit to register separately. This change is expected to alleviate administrative burdens and enhance the FDA's oversight capabilities. The proposed rule also addresses the registration requirements for foreign drug manufacturing establishments, particularly those producing active pharmaceutical ingredients (APIs) that enter the U.S. supply chain indirectly. Currently, some foreign manufacturers are not registered with the FDA, which limits the agency's ability to monitor the upstream supply chain. By mandating registration for these establishments, the FDA aims to improve transparency and safety in drug sourcing. Michael Davis, M.D., Ph.D., Acting Director of the FDA’s Center for Drug Evaluation and Research, emphasized that these changes reflect the realities of distributed manufacturing and will facilitate more efficient operations for innovative manufacturers. The FDA anticipates that the proposed rule will not only reduce registration costs for companies but also enhance the agency's ability to trace the origins of active ingredients in medications, thereby improving patient safety. If finalized, this rule will contribute to ongoing efforts to revitalize American pharmaceutical manufacturing and strengthen supply chain integrity. The FDA's commitment to ensuring reliable access to safe and quality medicines remains a priority, and this proposed rule is a significant step in that direction.

FDA News · 5d ago

GSK Terminates Collaboration with Alector Amidst Drug Development Setbacks

GlaxoSmithKline (GSK) has officially ended its collaboration with Alector, a California-based biotechnology firm, following significant setbacks in the development of two experimental brain drugs. Initially formed in July 2021, the partnership was valued at up to $2.2 billion, with GSK paying $700 million upfront for rights to Alector's neurodegenerative disease treatments, including latozinemab (AL001) and nivisnebart (AL101). However, both drugs faced critical failures in clinical trials, leading to the termination of the alliance on July 6, 2026. Latozinemab, which had progressed to late-stage trials, failed to demonstrate a significant impact on disease progression in a large study released last October. Similarly, an interim futility analysis prompted Alector to halt a Phase 2 trial of nivisnebart in early Alzheimer’s patients by late April. The termination of the partnership is expected to be finalized by January 2, 2027, following a prior amendment in May 2023 that shifted more financial responsibility for nivisnebart's development to Alector, reducing the initial deal value to approximately $572 million. The fallout from this collaboration is particularly impactful for Alector, which has seen its stock plummet by about 95% over the past five years, with shares trading at $1.70 following the announcement. The company has also faced multiple rounds of layoffs as it struggled with disappointing drug results, including a previous partnership with AbbVie that ended similarly. For GSK, this collaboration represented a significant re-entry into neuroscience, an area it had largely neglected for over a decade, and the failure of these drugs may hinder its ambitions in developing therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

BioPharma Dive · 6d ago

Prime Medicine Wins Legal Battle; Saol Resubmits FDA Application for Rare Disease Treatment

Prime Medicine has successfully resolved a legal dispute with Beam Therapeutics regarding their respective therapies for alpha-1 antitrypsin deficiency (AATD). An arbitration panel ruled that Prime did not breach a 2019 collaboration agreement with Beam, which had claimed that Prime's development of an AATD treatment violated their deal. This ruling allows Prime to continue its preclinical work on its 'prime editing' therapy without owing any damages to Beam, whose own AATD treatment is in advanced clinical trials. The outcome is significant as it underscores the competitive landscape in gene editing therapies for rare diseases. In another development, Saol Therapeutics has announced the resubmission of its application for SL1009, a treatment for pyruvate dehydrogenase complex deficiency, which the FDA previously rejected. Following a meeting with the FDA, Saol was advised to provide additional analyses rather than conduct another trial, reflecting a shift in regulatory flexibility that could benefit other companies in similar situations. Saol's progress is part of a broader trend where drugmakers are finding new pathways to approval after initial setbacks. Additionally, the European Medicines Agency has initiated a phased review of Revolution Medicines' daraxonrasib, a promising drug for pancreatic cancer that has shown nearly double the survival rate compared to chemotherapy in Phase 3 trials. This expedited review process is expected to set a precedent for future EU legislation aimed at enhancing the efficiency of drug evaluations. Meanwhile, Cyllene Therapeutics has secured $33 million in Series C funding to advance its gene therapy for neurogenic detrusor overactivity, with plans to initiate late-stage trials next year. These developments highlight the dynamic nature of the biotech industry and the ongoing efforts to address unmet medical needs.

BioPharma Dive · Jul 8

Oberland Capital Invests Up to $400M in MeiraGTx's Gene Therapies for Eye Diseases

MeiraGTx has secured up to $400 million in funding from Oberland Capital Management to advance its gene therapies targeting inherited eye conditions. The deal, announced recently, includes $375 million in financing and an additional $25 million equity investment. In exchange, Oberland will receive royalties on three gene therapy candidates currently in development, which aim to address various eye diseases. Among the therapies, one is for Leber congenital amaurosis-4, a rare blinding condition, which was previously licensed to Eli Lilly. MeiraGTx retains rights to the other two therapies: bota-vec for X-linked retinitis pigmentosa and AAV2-hAQP1 for radiation-induced xerostomia. The CEO of MeiraGTx, Alexandria Forbes, expressed that this investment reflects strong confidence in the clinical data and market potential of these therapies. The company anticipates reporting pivotal study data for AAV2-hAQP1 in the second quarter of next year, with a potential FDA approval in 2027 and a U.S. launch as early as 2028. Positive three-year data from earlier trials suggest that AAV2-hAQP1 may qualify for priority review by the FDA. However, the future of bota-vec remains uncertain after it failed to meet its primary endpoint in a late-stage trial last year, leading to Johnson & Johnson returning rights to MeiraGTx. Despite this, optimism persists regarding the therapy's potential benefits observed in testing. Oberland's partner, Michael Bloom, highlighted that MeiraGTx is uniquely positioned to potentially launch three therapies within the next two years, two of which address significant unmet medical needs, marking a notable advancement in the field of gene therapy for eye diseases.

BioPharma Dive · Jul 7

Kailera's Obesity Drug Shows Promise in Phase 3 Trial in China Despite Safety Concerns

Kailera Therapeutics has announced positive results from a Phase 3 trial of its GLP-1 pill, HRS-7535, aimed at treating obesity. The trial, conducted in China, demonstrated that participants lost an average of 9.8% of their body weight over 44 weeks. This outcome positions HRS-7535 as a potential competitor to existing weight loss medications from Eli Lilly and Novo Nordisk, particularly their products Foundayo and Wegovy, which have shown higher weight loss percentages in previous studies. However, the trial also raised concerns due to high rates of gastrointestinal side effects, with 70% of participants experiencing nausea and 67% to 69% reporting vomiting. The significance of these findings lies in the growing market for obesity treatments, where multiple options are being explored to cater to diverse patient preferences. While injectable medications like Zepbound and the experimental retatrutide may offer more substantial weight loss, oral medications like HRS-7535 provide a more convenient alternative for patients. Kailera's ongoing Phase 2 trial aims to address safety concerns by testing lower doses and exploring different dosing schedules. Despite the promising weight loss results, Kailera and its partner Hengrui Pharma must conduct further studies to validate the drug's effectiveness in broader populations, as the current trial's participants had a lower average body mass index. The company is also focused on ensuring that the safety profile of HRS-7535 improves, particularly in reducing gastrointestinal side effects, to enhance its competitiveness in the obesity treatment market. As the landscape of obesity medications evolves, the outcomes of Kailera's ongoing trials will be crucial in determining the drug's future in a crowded marketplace.

BioPharma Dive · Jul 7

EMA Initiates Phased Review of Daraxonrasib for Metastatic Pancreatic Cancer Treatment

The European Medicines Agency (EMA) has commenced a phased review of daraxonrasib, a novel treatment for metastatic pancreatic cancer. This decision follows promising results from a phase 3 clinical trial comparing daraxonrasib to standard chemotherapy in patients who have previously undergone treatment. Metastatic pancreatic cancer is associated with a grim prognosis, typically offering patients a life expectancy of only six months, highlighting the urgent need for effective therapies in this area. Daraxonrasib has been prioritized under the EMA's Cancer Medicines Pathfinder project due to its potential to meet significant unmet medical needs. The phased review process allows the EMA to evaluate data as it becomes available, potentially expediting the overall assessment timeline compared to traditional methods. This approach is part of a broader reform in EU pharmaceutical legislation aimed at enhancing the efficiency of drug evaluations and facilitating quicker patient access to innovative treatments. The CHMP's phased review will encompass quality, nonclinical, and clinical data, ensuring that daraxonrasib meets the rigorous standards for safety and efficacy. While the exact timeline for the review remains uncertain, it is anticipated to be shorter than standard evaluations, as parts of the assessment will occur prior to the submission of a complete marketing authorization application. Looking forward, the EMA plans to consider additional medicines for phased review, focusing on those that address unmet medical needs and hold significant public health interest.

EMA News · Jul 7

Cancer and Immune Drugmakers Lead VC Funding in 2026, Surpassing $3.9 Billion

In the first half of 2026, drug developers targeting cancer and autoimmune diseases captured over 40% of venture capital funding in the biotech sector, according to data from BioPharma Dive. A total of more than $9 billion was raised by 26 active investors, with approximately $3.9 billion allocated specifically to companies focused on these therapeutic areas. Notably, around $2.1 billion was directed towards immune drugmakers, many of which are developing experimental treatments for conditions such as lupus, atopic dermatitis, and inflammatory bowel disease. The trend of significant investment in cancer and immunology reflects a strategic focus by venture capitalists, as these fields lack the immediate time-sensitive pressures seen in other areas like obesity and cardiometabolic disorders. Analysts suggest that this trend is likely to continue, especially as major funding rounds have recently been secured by innovative companies such as Isomorphic Labs, which raised $2.1 billion for AI-driven drug discovery, and NewLimit, which garnered $435 million for longevity research. Additionally, companies like Parabilis Medicine and Beeline Medicines have also attracted substantial investments, with Parabilis raising $305 million for its oncology portfolio and Beeline securing over $426 million for its work on both small molecules and biologics targeting immune conditions. The interest from pharmaceutical companies in immune drugmakers is also on the rise, with significant acquisitions occurring in the sector, indicating a robust pipeline potential as firms seek to navigate upcoming patent expirations. As the year progresses, the public market has seen a surge in biotech IPOs, with six of the thirteen venture-backed companies that went public in 2026 focusing on cancer or immune therapies. Parabilis's IPO, which raised $670 million, stands out as the largest to date, underscoring the growing investor confidence in these therapeutic areas.

BioPharma Dive · Jul 6

EMA Enhances Focus on Women's Health in Medicine Development and Regulation

The European Medicines Agency (EMA) is intensifying its efforts to incorporate women's health considerations into the development and regulation of medicines. Despite women living longer than men, they often experience poorer health due to societal factors and gaps in disease prevention, diagnosis, and treatment. To address these disparities, EMA will host a dedicated workshop on women's health on September 28-29, which will be broadcast live. This workshop aims to assess current activities across the EU, including contributions from national regulators and other organizations, while identifying research gaps and priorities to enhance the evidence base for women's health. Key areas of focus include improving representation of women in clinical trials, ensuring that potential sex-specific differences in treatment are adequately assessed and reflected in product labeling, and enhancing information on the use of medicines during pregnancy and breastfeeding. EMA has already made strides in these areas, such as funding post-authorisation studies and developing guidelines for the safe inclusion of pregnant and breastfeeding individuals in clinical trials. The agency is also leveraging real-world evidence studies to better understand how medicines perform in diverse populations, particularly women. Looking ahead, EMA plans to reduce regulatory uncertainty by encouraging developers to utilize its early development support mechanisms to address methodological challenges in women's health medicine development. The outcomes of the upcoming workshop will be documented in a report, which will outline areas where further research and development are needed. This initiative is crucial for ensuring that women's specific health needs are met and that conditions like preeclampsia, menopausal symptoms, and endometriosis receive the attention they deserve.

EMA News · Jul 2

FDA Approves Casgevy: First Gene Therapy for Young Children with Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) has granted supplemental approval for Casgevy (exagamglogene autotemcel), marking a significant advancement in the treatment of sickle cell disease (SCD) and transfusion-dependent β thalassemia (TDT) for pediatric patients aged 2 years and older. This approval is particularly noteworthy as it is the first gene therapy available for young children suffering from SCD, a life-threatening blood disorder characterized by painful vaso-occlusive crises (VOCs). Previously, Casgevy was only approved for patients aged 12 and older. The FDA's decision is a response to the urgent need for effective treatments for these debilitating conditions, which can severely impact the growth and long-term health of affected children. The therapy utilizes the patient's own edited hematopoietic stem cells, employing CRISPR/Cas9 technology to enhance fetal hemoglobin levels, thereby preventing the formation of sickle-shaped red blood cells and reducing VOCs. In clinical trials, the therapy demonstrated promising results, with a significant percentage of patients achieving transfusion independence and a reduction in severe VOCs. The approval process for Casgevy was expedited, taking only 53 days from filing to decision, highlighting the FDA's commitment to addressing critical health priorities through initiatives like the Commissioner’s National Priority Voucher Pilot Program. This program aims to facilitate faster access to innovative therapies for diseases with significant unmet medical needs. The approval also comes with various designations, including Orphan Drug and regenerative medicine advanced therapy (RMAT), underscoring the therapy's potential impact. As healthcare professionals look to implement this groundbreaking treatment, it is essential to monitor the safety profile, which includes potential adverse reactions such as mucositis and febrile neutropenia. The approval of Casgevy represents a critical step forward in providing younger patients with access to effective therapies, ultimately improving their quality of life and health outcomes.

FDA News · Jul 1

BridgeBio Secures $1 Billion for Drug Launch; United Therapeutics Acquires Cell Therapy Startup

BridgeBio Pharma has announced a significant funding agreement with Sixth Street Partners and HealthCare Royalty, securing up to $1 billion in preferred equity to support its upcoming commercial launches. The initial conversion price is set at $137.79 per share, which is over a 100% premium compared to the company's average stock price. While the deal includes a 7.0% initial preferred dividend that may impact profitability, analysts view it as a lower-cost capital option compared to traditional equity. The funding breakdown includes $800 million from Sixth Street and $133.9 million from HealthCare Royalty. In another development, United Therapeutics has committed $140 million upfront to acquire Thymmune Therapeutics, a startup focused on cell therapy aimed at restoring thymus function in patients with congenital athymia, a rare condition leading to severe immunodeficiency. Thymmune's lead product, THY-100, utilizes human-induced pluripotent stem cells to generate thymic cells that can mature into T cells. The acquisition could yield an additional $160 million based on milestone achievements by 2031. Otsuka Pharmaceutical reported positive results from its Phase 3 trial of Voyxact, a drug for kidney function in patients with IgA nephropathy. The treatment demonstrated stabilization and improvement in kidney function over two years, supporting its traditional approval following an earlier accelerated approval for reducing protein in urine. Analysts anticipate that the promising data will enhance physician adoption of APRIL-targeting therapies. Lastly, the FDA has expanded the use of Vertex Pharmaceuticals' CRISPR therapy, Casgevy, to children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. This approval marks a significant milestone as Casgevy becomes the first gene therapy available for these conditions in young patients, potentially broadening its market reach amid previous sales challenges due to production complexities.

BioPharma Dive · Jul 1

Key FDA Decisions to Monitor in Q3 2026: Capricor, Takeda, Celcuity, and Moderna

As the third quarter of 2026 approaches, several significant FDA decisions are anticipated that could reshape treatment landscapes for various conditions. Capricor Therapeutics is awaiting a decision on its cell therapy, deramiocel, aimed at treating Duchenne cardiomyopathy, a severe complication of Duchenne muscular dystrophy. Following a previous rejection, Capricor has gathered additional data from a larger study, and the FDA is expected to announce its decision by August 22. A successful approval could not only benefit patients but also provide Capricor with a priority review voucher, enhancing its market position. Meanwhile, Takeda is poised to secure its foothold in the narcolepsy treatment market with its drug oveporexton, which targets orexin proteins to improve symptoms of Type 1 narcolepsy. The FDA's decision is anticipated by the end of September, with analysts projecting peak sales of $2 billion to $3 billion. The drug's approval could also open avenues for treating other conditions linked to orexin dysfunction, such as ADHD and various sleep disorders. Celcuity is also in the spotlight with its drug gedatolisib, targeting PIK3CA mutations in advanced breast cancer. The FDA's decision is due by July 17, following promising but mixed results from clinical trials. While initial data showed significant efficacy, subsequent findings raised questions about treatment regimens. Analysts remain cautiously optimistic about gedatolisib's potential to establish a new standard of care for specific breast cancer patients. Lastly, Moderna is seeking approval for its mRNA-1010 vaccine for seasonal influenza, which could mark a pivotal moment for the company as it navigates regulatory challenges. This decision could signal a shift in the FDA's approach to mRNA technologies beyond COVID-19, potentially impacting future vaccine development strategies. Collectively, these decisions highlight the evolving landscape of drug approvals and their implications for patients and the healthcare market.

BioPharma Dive · Jul 1

Viridian's Lumvoa Approved, Poised to Compete with Amgen's Tepezza in Thyroid Eye Disease Market

The FDA has approved Viridian Therapeutics' Lumvoa for the treatment of thyroid eye disease, positioning it as a potential competitor to Amgen's Tepezza, which has dominated the market. This autoimmune condition, often associated with Graves' disease, leads to inflammation around the eyes, causing pain, bulging, and vision impairment. Analysts suggest that Lumvoa's approval could disrupt the existing market dynamics, as it offers a more favorable dosing schedule and broader treatment indications compared to Tepezza. Lumvoa requires five infusions every three weeks, lasting 30 to 40 minutes, compared to Tepezza's eight infusions over a longer duration. This difference in administration could enhance physician adoption and expand the patient population treated for both active and chronic thyroid eye disease. Analysts from Leerink Partners and Jefferies have noted that while Lumvoa's pricing aligns with Tepezza at approximately $450,000, its revenue growth may take time to materialize, with projections estimating around $738 million by 2035. Viridian plans to launch Lumvoa immediately, marking its first marketed product. Additionally, the company is advancing its other program, elegrobart, which targets chronic thyroid eye disease, with plans to submit for regulatory approval in early 2027. This strategic move indicates Viridian's commitment to capturing a larger share of the thyroid eye disease market, potentially reshaping treatment options for patients in the future.

BioPharma Dive · Jun 30

FDA Launches PreCheck Pilot Program to Strengthen U.S. Drug Manufacturing with Seven Selected Companies

The U.S. Food and Drug Administration (FDA) has announced the selection of seven companies to participate in its PreCheck Pilot Program, aimed at enhancing domestic pharmaceutical manufacturing and improving the resilience of the U.S. drug supply chain. This initiative, launched on February 1, 2026, is a response to Executive Order 14293, signed by President Trump, which seeks to bolster American competitiveness in the pharmaceutical sector. The program is designed to facilitate the establishment of new manufacturing facilities in the U.S. by providing earlier FDA engagement and a more predictable regulatory pathway for companies. The selected companies include Amneal Pharmaceutical, Cellares Corp., Eli Lilly and Company, FUJIFILM Biotechnologies, Kriya Therapeutics, Kyowa Kirin, and Regeneron Pharmaceuticals. Each company will manufacture various drug products, including small molecule sterile liquids, cell-based gene therapies, and biotechnology drug substances, addressing critical medical needs across multiple disease areas. The FDA received over 80 applications for the program, highlighting the significant interest in domestic manufacturing capabilities. The PreCheck Pilot Program consists of two phases: Phase 1 focuses on facility readiness, allowing companies to receive early technical guidance from the FDA, while Phase 2 emphasizes application submission with enhanced engagement opportunities. This structured approach aims to minimize uncertainties related to manufacturing readiness and expedite the availability of essential medicines for American patients. The FDA will continue to monitor the program's implementation and explore further opportunities for development, reinforcing its commitment to a robust domestic pharmaceutical manufacturing landscape.

FDA News · Jun 29

Zymeworks Acquires Theravance Biopharma for $929 Million Following Drug Development Challenges

Zymeworks, a royalty management company, has announced its acquisition of Theravance Biopharma for $929 million, a strategic move following Theravance's recent clinical setbacks, particularly the failure of its drug ampreloxetine in a Phase 3 trial for low blood pressure related to multiple system atrophy. The deal, which was made public on June 29, 2026, includes partial rights to Theravance's COPD medication Yupelri and potential future payments from its collaboration with GSK on Trelegy, as well as an antibiotic for hospital-acquired infections. Under the terms of the acquisition, Zymeworks will pay $17 per share, with additional potential payouts linked to the licensing or sale of ampreloxetine. The company is financing part of the acquisition through a $350 million loan from Omers Life Sciences, which will be repaid using cash flow generated from Yupelri. This acquisition comes after Theravance initiated a strategic review of its business in 2024, which intensified after the disappointing trial results for ampreloxetine earlier this year. Theravance Biopharma, which was spun out from Theravance Inc., has historically focused on developing and commercializing experimental drugs while retaining economic rights to certain GSK respiratory products. The company's valuation has significantly relied on the revenue from Yupelri, which generated $75 million in 2025, and an anticipated $100 million milestone payment from Trelegy expected next year. The acquisition offer represents a 22% premium over Theravance's stock price prior to the release of the ampreloxetine trial data. Zymeworks anticipates that the acquisition will be immediately profitable upon closing, projected by the end of the year. Analysts have praised the deal structure for its creativity, allowing Zymeworks to minimize cash outlays while still pursuing a $125 million share buyback program. This acquisition marks a significant step for Zymeworks as it expands its portfolio in the royalty management sector.

BioPharma Dive · Jun 29

Key Clinical Trials to Monitor in Late 2026: PD-1/VEGF Inhibitors and Cobenfy's Potential

As the second half of 2026 approaches, several pivotal clinical trials are set to shape the future of oncology and neurology. Notably, the Harmoni-3 trial, conducted by Akeso and Summit Therapeutics, aims to evaluate the efficacy of ivonescimab combined with chemotherapy against the established Keytruda regimen in treating non-small cell lung cancer (NSCLC). This global trial is crucial as it seeks to clarify the role of PD-1/VEGF inhibitors, which have shown promise but faced skepticism due to mixed results from previous studies. The success of Harmoni-3 could revolutionize treatment protocols for NSCLC, a prevalent cancer worldwide, and potentially extend the application of PD-1/VEGF therapies to other malignancies. In parallel, Bristol Myers Squibb is focusing on its acquisition of Karuna Therapeutics and the drug Cobenfy, initially aimed at schizophrenia treatment. With disappointing sales figures, the company is now testing Cobenfy's effectiveness in treating Alzheimer’s disease-related psychosis through the ADEPT-2 trial. Given the significant number of Alzheimer’s patients experiencing psychosis, a successful outcome could open a lucrative market for Bristol Myers, despite recent irregularities in trial conduct raising concerns among analysts. Additionally, Celldex Therapeutics is set to report results from its Embarq-CSU1 and Embarq-CSU2 trials, which focus on chronic spontaneous urticarias. After a strategic pivot from oncology to inflammatory skin conditions, Celldex's barzolvolimab could address a substantial unmet need in treating debilitating itching disorders. With millions affected in the U.S. and limited effective treatments available, positive trial outcomes could position Celldex as a key player in this therapeutic area. As these trials progress, the implications for patient care and market dynamics in oncology and neurology will be closely watched by healthcare professionals and investors alike.

BioPharma Dive · Jun 29

U.S. Biotech Faces Regulatory Tensions Amid Surge in Chinese Licensing Deals

The U.S. biotechnology sector is experiencing heightened scrutiny and tension over a significant increase in licensing agreements with Chinese pharmaceutical companies. Since the beginning of 2025, nearly 100 such deals have been publicly announced, raising concerns among U.S. lawmakers regarding national security and market competition. The Biotechnology Innovation Organization (BIO) recently held its annual meeting, where discussions centered on the implications of these agreements for business development and venture investments in the biotech landscape. BIO CEO John Crowley emphasized the dual challenges facing the U.S. biotech ecosystem: the need to protect national interests while also fostering competitive advantages against Chinese firms. Recent high-profile deals, including those between Pfizer and Innovent Biologics, and Bristol Myers Squibb and Hengrui Pharmaceuticals, highlight the growing importance of Chinese-origin assets in U.S. strategic pipelines. Analysts note that these collaborations are evolving from opportunistic partnerships to core components of major pharmaceutical strategies. The regulatory environment is shifting, with proposals to scrutinize investments in the biotech sector more closely. The Biosecure Act, signed into law in December, imposes new compliance requirements on U.S. companies working with certain Chinese suppliers, which some experts argue could hinder competitiveness. Critics warn that restricting access to Chinese efficiencies may ultimately disadvantage U.S. firms. In response to these challenges, the Department of Health and Human Services is proposing measures to accelerate early drug research in the U.S., aiming to clarify regulatory pathways and enhance collaboration with research institutions. As both nations implement new initiatives to bolster their pharmaceutical sectors, American companies continue to pursue substantial partnerships with Chinese firms, indicating a complex interplay of competition and collaboration in the global biotech arena.

BioPharma Dive · Jun 26

CHMP Recommends Six New Medicines and Reviews Existing Treatments in June 2026 Meeting

During its June 2026 meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for marketing authorization, highlighting significant advancements in treatment options for various conditions. Among the approved medicines is Aujemflu, an inactivated influenza vaccine aimed at individuals aged 50 and older, which addresses the increased risk of severe influenza in this age group. Additionally, Hopledo, a combination of levodopa and carbidopa, is set to aid adult patients with Parkinson's disease who experience moderate-to-severe motor fluctuations, providing a new option for those inadequately managed by existing therapies. Onswik, an insulin formulation, received a positive opinion for treating type 2 diabetes in adults, while two biosimilars, Denosumab Ascend and Nylaspeg, were also endorsed for their roles in preventing bone complications in cancer patients and reducing chemotherapy-induced neutropenia, respectively. Notably, after a re-examination, Daybu was recommended for marketing authorization to treat neurobehavioral symptoms of Rett syndrome, albeit with a restricted indication, following an initial refusal. Conversely, the committee issued negative opinions for three medicines, including Tacquell for advanced melanoma and Yartemlea for HSCT-associated thrombotic microangiopathy, indicating ongoing challenges in developing effective treatments for complex conditions. Furthermore, the CHMP recommended extending the indication for Imvanex, a smallpox vaccine, to include children aged two and older, reflecting a proactive approach to public health. The meeting also saw the initiation of a review for Rifadin due to concerns over a potentially carcinogenic excipient, and the revocation of Tavneos' marketing authorization due to questions about data integrity. These developments underscore the CHMP's commitment to ensuring the safety and efficacy of medicinal products in the EU, as well as its responsiveness to emerging safety concerns.

EMA News · Jun 26

RQ Bio Secures $115M to Develop Innovative Influenza Preventive Drug RQB01

Biotechnology startup RQ Bio has successfully raised $115 million in a funding round aimed at advancing its innovative influenza preventive drug, RQB01. This London-based company claims that RQB01 utilizes a unique dual mechanism to target stable components of the influenza virus, potentially offering long-lasting protection against various strains with just a single dose. Currently in preclinical testing, the drug aims to address the limitations of existing flu vaccines, which can vary in effectiveness and may not be suitable for all patients due to allergies. The funding round was led by Frazier Life Sciences, with participation from LifeArc Ventures, Forbion, and EQT Life Sciences. Joe Cabral, a partner at Frazier Life Sciences, expressed confidence in RQB01's potential to provide effective, season-long flu prevention, particularly for vulnerable populations at high risk of severe illness. This development is crucial as influenza continues to pose a significant public health challenge, with existing vaccines not universally effective and on-demand treatments offering limited benefits. In addition to RQB01, RQ Bio is also exploring preventive therapies for other respiratory viral infections. The company has appointed Christian Schade, former president and CEO of Halda Therapeutics, as its executive chairman, signaling a strategic move to bolster its leadership as it navigates the competitive landscape of influenza prevention. As the flu season approaches, the success of RQB01 could represent a significant advancement in public health strategies against influenza.

BioPharma Dive · Jun 24

Psychedelics Biotechs Thrive Together Amid Positive Clinical Results

Recent developments in the psychedelics biotech sector highlight a unique trend where companies appear to support rather than compete against each other. Following positive clinical trial results from Compass Pathways, which evaluated a synthetic version of psilocybin, multiple psychedelics developers, including Definium Therapeutics, saw their stock prices rise. Definium's late-stage trial results for an LSD formulation demonstrated significant efficacy in treating major depression, leading to a nearly 50% increase in its stock price. Analysts have projected peak sales for this drug to reach between $1.5 billion and $2 billion, indicating strong market potential. This collaborative atmosphere among psychedelics companies is attributed to the emerging nature of the field, which has historically faced stigma and regulatory challenges. As attitudes shift and clinical results become more favorable, the market for psychedelics is gaining traction. Analysts suggest that the presence of multiple players in this space can enhance infrastructure development and patient adoption, rather than creating direct competition. The market for depression treatments is robust, with patients often switching medications due to side effects or inadequate symptom control. This dynamic creates opportunities for several psychedelics products to coexist, as they will primarily compete against traditional antidepressants like SSRIs. The ongoing evolution of the psychedelics market is expected to continue, with companies like Compass and Definium potentially growing together in both patient and investor interest.

BioPharma Dive · Jun 24

Sangamo Therapeutics Files for Bankruptcy; Eli Lilly and Astellas Lead Asset Auction

Sangamo Therapeutics, a pioneer in gene editing technology, has filed for bankruptcy and is set to auction its assets. Eli Lilly and Astellas Pharma are the lead bidders for Sangamo's gene editing tools and therapies, including an experimental treatment for prion disease and a Fabry disease therapy nearing regulatory approval. This auction is part of a court-supervised process that will also include other experimental therapies targeting chronic pain and hemophilia A. Sangamo has struggled to bring products to market, facing multiple restructurings and lost partnerships over the years. In a related development, Serapha Bio, a new competitor in the gene editing space linked to China, has secured $230 million in funding to advance its treatment for alpha-1 antitrypsin deficiency. This company plans to go public through a reverse merger with Boundless Bio, a struggling cancer drugmaker. Serapha's therapy is in an investigator-initiated trial in Shanghai and competes with a treatment from Beam Therapeutics that is in advanced clinical development. Additionally, Merck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a startup focused on rare genetic heart diseases. Merck is providing $50 million in initial funding under a 'build-to-buy' agreement, allowing them to acquire the company at a pre-negotiated price. In other news, Sanofi has received European approval for Cenrifki (tolebrutinib), a BTK inhibitor for secondary progressive multiple sclerosis, despite mixed study results and a prior FDA rejection. Meanwhile, CARsgen Therapeutics has achieved a milestone with the first regulatory clearance of a CAR-T therapy for solid tumors in China, specifically for gastric tumors expressing Claudin18.2, showcasing advancements in cancer treatment options.

BioPharma Dive · Jun 24

Pfizer's Sigvotatug Vedotin Fails Key Lung Cancer Trial, Impacting Future Revenue Prospects

Pfizer Inc. has reported a significant setback with its experimental cancer drug, sigvotatug vedotin, which failed to demonstrate a meaningful survival advantage over standard chemotherapy in a Phase 3 trial for advanced non-squamous non-small cell lung cancer. This trial was closely monitored as the drug is part of Pfizer's $43 billion acquisition of Seagen, a deal that was expected to bolster the company's oncology portfolio and revenue growth. The failure of this trial is particularly concerning given that Pfizer has already faced approximately $4.5 billion in write-offs due to various development challenges and competitive pressures. Despite the disappointing results, Pfizer remains optimistic about the drug's potential, especially in an upcoming study evaluating sigvotatug vedotin in combination with Merck's Keytruda for first-line lung cancer treatment. This trial is anticipated to yield results in 2027 and could provide a critical opportunity for the drug to prove its efficacy in a different patient population. Analysts note that the bar for success is high, given previous failures of similar drugs in comparable settings. The company has indicated a “stronger trend” in survival for patients who had received only one prior line of treatment, which may bolster confidence in the drug's future prospects. However, the negative outcome from the recent trial eliminates one of the two major catalysts for Pfizer this year, leaving the success of another drug, mevrometostat, in prostate cancer as the sole remaining focus for potential growth. The implications of this trial failure extend beyond Pfizer, as it reflects the challenges faced by the oncology sector in developing effective treatments for complex cancers.

BioPharma Dive · Jun 23

Eli Lilly Cuts 340B Discounts, Prompting Hospital Outcry and Calls for Regulatory Action

Eli Lilly has implemented a controversial policy that halts drug discounts under the 340B program for hospitals that do not comply with new paperwork requirements. This decision, which affects select hospitals, has drawn significant backlash from healthcare providers and organizations, including the American Hospital Association (AHA) and 340B Health, who argue that it undermines patient access to affordable medications. The 340B program, established to assist financially strained providers in affording high-cost drugs, is now at risk as hospitals face increased costs due to Lilly's enforcement of compliance measures. Lilly's policy requires hospitals to submit claims data for all drugs dispensed under the 340B program, a move the company claims is necessary to prevent fraud and abuse. However, hospitals contend that this requirement is illegal and that Lilly lacks the authority to condition discounts on data sharing. The AHA and 340B Health have urged federal regulators to intervene, fearing that if Lilly's policy goes unchecked, other pharmaceutical companies may adopt similar practices, further jeopardizing the integrity of the 340B program. The financial implications for affected hospitals are significant, as they will now have to purchase Lilly drugs at wholesale prices, losing discounts that typically range from 20% to 50%. This shift contradicts the original intent of the 340B program, which was designed to alleviate the financial burden on healthcare providers. The ongoing disputes over the 340B program have intensified as its usage has surged, with hospitals reporting record purchases of $66.3 billion in 2023, a 50% increase from two years prior. As the situation develops, the healthcare community is closely monitoring potential regulatory responses from the Health Resources and Services Administration (HRSA) and the Department of Health and Human Services (HHS).

BioPharma Dive · Jun 23

Bionyra Secures $165M to Advance Next-Gen Biologics for Immune Disorders

Bionyra, a newly launched biotechnology firm, has raised $165 million in a Series A funding round to develop innovative biologics targeting immune diseases. Co-founded by Sofinnova Partners and Frédéric Marrache, a former Sanofi immunology R&D head, Bionyra is advancing three drug candidates into clinical trials, including BYN-002, a monoclonal antibody aimed at treating inflammatory bowel disease (IBD), and BYN-003, a bispecific antibody that combines TL1A with IL-23. Both candidates are currently in Phase 1 studies, with BYN-002 designed to have an extended half-life for improved efficacy. The company’s third asset, BYN-001, is an anti-IL-25 monoclonal antibody intended for use in atopic dermatitis and other inflammatory conditions. Bionyra plans to administer BYN-001 as a quarterly or biannual injection, potentially allowing for combination therapies with existing treatments. The current landscape for immune disease therapies includes IL-23 inhibitors, anti-integrin therapies, and JAK inhibitors, each with limitations such as partial patient response and safety concerns, particularly with JAK inhibitors facing black box warnings from the FDA. Bionyra's approach reflects a growing trend in the biotech sector, where companies are exploring novel biologics to address unmet needs in immune disease treatment. The funding round was co-led by Sofinnova and Jeito Capital, with participation from several other investors, indicating strong confidence in Bionyra's potential to innovate in this competitive field. As the company progresses through clinical trials, it aims to establish itself as a leader in the next generation of biologics, focusing on efficacy improvements over existing therapies.

BioPharma Dive · Jun 22

The Crucial First 14 Days in Specialty Medication Management

The initial two weeks following a prescription for specialty medications are pivotal for patient adherence and treatment success. As specialty therapies become increasingly integral to healthcare, the patient journey post-prescription is critical. Research indicates that nearly 50% of patients do not adhere to their prescribed therapies, with abandonment rates soaring to 67% for oral cancer treatments and over 50% for anti-inflammatory drugs. Effective communication and support during this period can significantly influence treatment outcomes and brand performance. During the first day, proactive engagement through onboarding calls or texts is essential to inform patients about their prescriptions and build trust. Nearly 95% of specialty patients receive communication within a day of their prescription being processed. The subsequent days focus on navigating access and prior authorization, where 94% of physicians acknowledge that prior authorization can delay care. Specialty pharmacy teams play a crucial role in expediting this process, ensuring that patients remain engaged and informed. Affordability is another major hurdle, with abandonment rates climbing to 60-70% when patient costs exceed $250. Specialty pharmacies, like Walgreens, are implementing dedicated support teams to assist patients in understanding their financial responsibilities and connecting them with assistance programs. This approach has shown significant results, particularly in oncology, where 56% of patients incur no copay for their therapies. As patients begin therapy, ongoing support is vital to address potential side effects and treatment adjustments. Specialty pharmacy teams are trained to manage these challenges, ensuring that patients receive the necessary guidance throughout their treatment journey. By enhancing communication and support during these critical early days, healthcare providers can improve patient adherence and overall treatment success.

BioPharma Dive · Jun 22

AI Revolutionizes Women's Health Marketing: A Shift Towards Lifelong Engagement

The landscape of women's health marketing is poised for transformation as brands begin to recognize the importance of fostering long-term relationships with women throughout their health journeys. Traditionally, marketing efforts have focused on isolated health events, failing to acknowledge the continuous nature of women's health from adolescence through menopause and beyond. This disjointed approach not only neglects the complexities of women's health but also overlooks the significant economic implications of addressing these issues. According to the World Economic Forum and McKinsey Health Institute, women spend 25% more of their lives in poor health compared to men, and closing the women's health gap could contribute an estimated $1 trillion to global GDP by 2040. The current state of funding for women's health is stark, with only 1% of healthcare research and innovation funding directed towards female-specific conditions outside of oncology. This underinvestment is particularly concerning given that women make approximately 80% of healthcare decisions for their families. However, recent trends indicate a shift, with PwC noting that women's health is moving from a niche market to a mainstream focus. Venture funding for women's health reached $2.6 billion in 2024, reflecting a 55% increase from the previous year, signaling a readiness for brands to engage more deeply with this demographic. Artificial intelligence (AI) is emerging as a critical tool in this evolution, enabling brands to connect various health conversations over time and provide personalized engagement. By integrating hormonal, metabolic, and behavioral data, AI can help brands understand where women are in their health journeys and anticipate their needs. A recent NVIDIA survey revealed that 70% of healthcare organizations are now utilizing AI, with 85% reporting increased revenue as a result. This capability allows for a shift from reactive marketing strategies to proactive, relationship-building approaches that prioritize preventive care. As the industry stands at this pivotal moment, the challenge for marketers is to responsibly leverage AI to foster trust and engagement with women. Brands that choose to build lasting relationships rather than transactional interactions will not only close the existing health gap but also redefine the future of women's health marketing. The choice is clear: embrace a holistic view of women's health or risk being left behind in a rapidly evolving landscape.

BioPharma Dive · Jun 22

Moderna's mRNA Flu Vaccine Gains FDA Panel's Unanimous Support, Paving Way for Approval

Advisers to the FDA have unanimously endorsed Moderna's experimental flu vaccine, mRNA-1010, indicating a significant step towards regulatory approval. The panel voted 9-0, asserting that the benefits of the vaccine outweigh its risks for adults aged 50 to 64, and similarly for those aged 65 and older. A decision from the FDA is anticipated by August 5. The vaccine, which utilizes messenger RNA technology, aims to enhance preparedness against emerging influenza strains and improve vaccination efficacy in populations that experience a high burden of influenza. The FDA's panelists praised the robustness of the studies presented, with experts noting that the data convincingly demonstrated the vaccine's effectiveness, reducing influenza illness likelihood by 27% compared to standard vaccines. Despite previous setbacks in the approval process, including a public dispute with the FDA over data adequacy, Moderna's application has gained renewed momentum following changes in FDA leadership and a reassessment of regulatory standards. Concerns were raised regarding the limited data on the vaccine's performance in frail older adults and immunocompromised individuals, as well as its efficacy against the influenza B strain. However, the FDA identified no major deficiencies in the application, which has bolstered confidence among analysts regarding the vaccine's approval prospects. Moderna has committed to conducting a confirmatory trial involving up to 800,000 participants over two flu seasons to further validate the vaccine's benefits. As the FDA moves closer to a decision, the outcome could significantly impact public health strategies for influenza vaccination, particularly in vulnerable populations. The approval of mRNA-1010 could also set a precedent for the use of mRNA technology in seasonal vaccines, following its success in COVID-19 vaccine development.

BioPharma Dive · Jun 18

Kardigan Raises $400M in IPO, Continuing Biotech's Surge in 2026

Kardigan, a cardiovascular drug startup, has successfully priced a $400 million initial public offering (IPO), marking a significant milestone in the biotech sector. This offering makes Kardigan the fourth biotech company in 2026 to raise at least $400 million, contributing to a total of 13 venture-backed biotech IPOs this year, surpassing the total from 2025. The median amount raised by biotech companies in 2026 has now reached nearly $302 million, a notable increase compared to the previous five years. Founded by former MyoKardia executives, Kardigan is advancing a portfolio of cardiovascular treatments, including its lead drug, danicamtiv, which is in late-stage testing for dilated cardiomyopathy, a condition currently lacking approved therapies. Initial studies suggest danicamtiv may enhance heart function in affected patients, with pivotal trial results anticipated in the first half of 2027. In addition to danicamtiv, Kardigan is developing ataciguat, a treatment for calcific aortic valve stenosis, which has shown promise in slowing disease progression and reducing calcium buildup. Further Phase 2 data for this drug is expected next year. Kardigan has also acquired tonlamarsen, an antisense oligonucleotide aimed at managing acute severe hypertension, with initial trial results expected in 2027. Kardigan's IPO reflects a broader trend of increasing investment in biotech, particularly in cardiovascular innovations. The company will commence trading on the Nasdaq under the ticker symbol 'KARD,' as it seeks to leverage its substantial funding to advance its clinical programs and address unmet medical needs in heart disease.

BioPharma Dive · Jun 18

Vedana Therapeutics Launches to Develop New Migraine Treatments Targeting PACAP

Vedana Therapeutics, a new biotech startup, has emerged with a focus on developing innovative therapies for migraine prevention. This initiative comes in response to the limitations of existing CGRP-blocking medications, which, while effective for many, fail to provide relief for over half of migraine patients. Vedana aims to address this treatment gap by targeting PACAP, a protein implicated in migraine pathology, through antibody drugs. This approach is distinct from the CGRP-targeting therapies currently available. The competitive landscape for migraine treatments is intensifying, with established players like Lundbeck, which acquired Alder BioPharmaceuticals and its anti-PACAP drug, already making strides in this area. Other companies, such as Mentari Therapeutics and Slate Medicines, are also pursuing similar pathways, indicating a robust interest in migraine therapeutics. Vedana's leadership team, which includes veterans from successful migraine drug development programs, is touted as a key differentiator in their approach. Backed by Westlake BioPartners and Canaan Partners, Vedana has secured $46 million in Series A funding, which is expected to support the advancement of its two main programs into human trials next year. One program focuses solely on PACAP, while the other combines targeting PACAP with CGRP, potentially enhancing efficacy for patients who do not respond to single-agent therapies. The startup's strategic focus on leveraging extensive industry experience aims to deliver next-generation migraine treatments that meet patient needs more effectively. As Vedana prepares to enter clinical trials, the migraine treatment landscape may see significant shifts, particularly for patients who have not found relief with existing therapies. The company's name, derived from Sanskrit, reflects the dual nature of migraine experiences, emphasizing both pain and the potential for relief. This innovative approach could pave the way for more effective management of migraines in the future.

BioPharma Dive · Jun 17

Eli Lilly Acquires 4E Therapeutics to Expand Non-Opioid Pain Treatment Pipeline

Eli Lilly has announced its acquisition of 4E Therapeutics, a biotechnology company focused on developing non-opioid pain treatments. This strategic move is part of Lilly's ongoing efforts to enhance its portfolio in the pain management sector, particularly as the company has invested over $18 billion in acquisitions in recent years. The acquisition provides Lilly with access to a pipeline of experimental drugs, including 4ET1103, which targets nerve damage-related pain and has shown safety in early human trials. 4E Therapeutics specializes in MNK inhibitors, which target specific enzymes involved in cellular signaling pathways. The company has also been developing treatments for migraines and acute pain, with funding of nearly $10 million from private investors and the National Institutes of Health. The financial terms of the acquisition have not been disclosed, but the deal is expected to bolster Lilly's commitment to addressing chronic pain challenges faced by patients. This acquisition marks Lilly's second purchase of a non-opioid pain drugmaker in two years, following its acquisition of SiteOne Therapeutics last year, which focuses on sodium ion channel-targeting drugs. Despite these acquisitions, Lilly has faced challenges in pain drug research, having discontinued two pain drugs from its pipeline recently. The company continues to diversify its portfolio, having also acquired Centessa Pharmaceuticals for $6.3 billion, which is developing treatments for sleep disorders, among other targets in genetic and immune therapies. As Lilly integrates 4E Therapeutics into its operations, the pharmaceutical giant aims to leverage its clinical development and commercial capabilities to maximize the potential of these innovative pain treatments, addressing a significant unmet need in the healthcare market.

BioPharma Dive · Jun 16

Express Scripts and PCMA Challenge Tennessee Law Restricting PBM Ownership of Pharmacies

Express Scripts, a subsidiary of Cigna, and the Pharmaceutical Care Management Association (PCMA) have filed lawsuits in federal court to block Tennessee's Freedom, Access and Integrity in Registered Pharmacy (FAIR Rx) Act, which prohibits pharmacy benefit managers (PBMs) from owning pharmacies in the state. The plaintiffs argue that the law is unconstitutional and could disrupt access to prescription medications for hundreds of thousands of patients by forcing PBM-owned pharmacies to close. This legal action follows a similar lawsuit from CVS Caremark, which claims the law would necessitate the closure of 136 pharmacies and halt mail-order services in Tennessee. The FAIR Rx Act, passed in May, aims to address concerns that PBMs are using their market power to undermine independent pharmacies. The law is set to take effect in 2028 and is expected to redirect billions of dollars from out-of-state operators to local pharmacies. The PBM industry has heavily lobbied against the legislation, spending over $7 million and employing more than 60 lobbyists to challenge its implementation. Cigna's lawsuit highlights the potential impact on its Memphis facility, which manages a significant portion of its operations and holds approximately $900 million in inventory. The facility serves nearly half a million patients nationwide, and its closure would severely limit access to specialized medications for Tennessee residents. Both Express Scripts and PCMA assert that the law violates the Constitution's Dormant Commerce Clause and conflicts with federal statutes like ERISA and TRICARE. The legal challenges reflect a growing trend, as at least nine other states are considering similar legislation to restrict PBM ownership of pharmacies. Independent pharmacies have long criticized PBMs for practices that limit their reimbursement and drive them out of business. As Congress has yet to enact comprehensive PBM reform, states are stepping in to address these competitive concerns, although PBMs maintain that their ownership structures do not create conflicts of interest.

BioPharma Dive · Jun 16

Edgewise's EDG-7500 Shows Promise in Phase 2 Trial for Cardiomyopathy

Edgewise Therapeutics has announced that its experimental drug, EDG-7500, successfully met the primary goals of a Phase 2 clinical trial aimed at treating both obstructive and non-obstructive forms of cardiomyopathy. The trial demonstrated a reduction in disease symptoms and biological markers, indicating potential improvements in blood flow and heart failure symptoms for patients with thickened heart muscles. This development is particularly significant as Edgewise pivots its focus from muscular dystrophy to cardiovascular diseases, following the sale of its muscular dystrophy pipeline. Despite the positive trial results, the company faces stiff competition from established treatments such as Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo. Analysts have mixed views on the trial's outcomes; while some see the data as a positive indicator of EDG-7500's competitive profile, others express concerns about the drug's efficacy in non-obstructive cardiomyopathy, where expectations were not fully met. The trial, known as “Cirrus-HCM,” primarily assessed safety but also included efficacy measures related to symptoms and quality of life. Participants in the trial reported significant improvements, with those suffering from obstructive cardiomyopathy showing a mean increase of 24 points on a symptom questionnaire, while non-obstructive patients saw a 13-point increase. Importantly, EDG-7500 did not adversely affect the left ventricular ejection fraction, a common concern with other treatments. However, two cases of atrial fibrillation were reported, raising questions about potential risks in larger studies. Looking ahead, the timeline for a Phase 3 trial is projected for 2028 or 2029, leaving analysts uncertain about the immediate impact of these results on investor sentiment and the drug's market potential. As Edgewise continues to navigate the competitive landscape of cardiomyopathy treatments, the upcoming studies will be crucial in determining the future of EDG-7500 and the company's strategic direction.

BioPharma Dive · Jun 16

FDA Grants Accelerated Approval for Tzield in Pediatric Stage 3 Type 1 Diabetes

On June 12, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Tzield (teplizumab) to delay the decline of insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 type 1 diabetes (T1D). This marks a significant milestone as it is the first FDA-approved treatment specifically for this indication, addressing a critical need in the pediatric diabetes community. The approval is based on robust clinical trial data demonstrating a statistically significant effect on C-peptide levels, a biomarker indicative of insulin production capacity. The FDA's decision highlights the urgent unmet needs of children with type 1 diabetes, as stated by Dr. Mahtab Niyyati, Acting Associate Director for Therapeutic Review. Tzield was previously approved for delaying the onset of Stage 3 T1D in adults and children over one year old with Stage 2 T1D. The new indication aims to provide a therapeutic option that may alter the disease's progression in younger patients. Healthcare professionals are advised to review the prescribing information, which includes a boxed warning about serious risks such as viral reactivation, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Common side effects reported include vomiting, rash, increased liver transaminase levels, and headache. Additionally, Tzield is associated with leukopenia, which may elevate the risk of infections. A postapproval study is currently underway to further verify the clinical benefits of Tzield in this patient population.

FDA News · Jun 15

EMA Management Board Highlights Progress on Crisis Response and Regulatory Initiatives

During the June 2026 meeting, the European Medicines Agency (EMA) Management Board discussed significant advancements in crisis preparedness, particularly in response to the Ebola outbreak in the Democratic Republic of Congo and Uganda. This marks the first public health emergency where EMA's Emergency Task Force collaborates with the newly established African Medicines Agency (AMA) and national regulatory authorities to facilitate clinical trial designs and medical countermeasures. This partnership aims to enhance regulatory responses to health emergencies, leveraging EMA's previous experiences with African regulators during past Ebola outbreaks. The Board also reviewed the Executive Director's 2025 annual activity report, highlighting EMA's successful issuance of 104 positive recommendations for new human medicines, including 38 with new active substances. Additionally, the agency provided 30 recommendations for veterinary medicines, marking a record high for the second consecutive year. These efforts underscore EMA's commitment to addressing unmet medical needs and ensuring the availability of medicines. Preparations for the new EU pharmaceutical legislation (NPL) are underway, with the Board receiving updates on governance structures and collaborative models to involve experts from the European medicines regulatory network. Future initiatives include a joint training program for Francophone regulators and the establishment of a memorandum of understanding to enhance cooperation in medicines regulation. Furthermore, the Board reported on the progress of clinical trials in the EU, noting over 14,000 applications submitted since the Clinical Trials Regulation went live in early 2022. The EMA is also enhancing its product management service to improve regulatory activities and transparency, with plans to release a beta version of an Application Programming Interface (API) for public access to medicinal product data by June 2026, aiming for a final version in early 2027.

EMA News · Jun 15

Strategic Approaches for Transitioning Injectable Molecules from Lab to Clinical Trials

As injectable molecules approach the clinical trial phase, drug developers face critical decisions that can significantly impact the success of their products. The urgency to initiate human trials often leads to a focus on speed; however, a strategic approach is essential to ensure robust manufacturability and regulatory compliance. Collaborating with a forward-thinking Contract Development and Manufacturing Organization (CDMO) can provide the necessary expertise to navigate this complex transition effectively. Key principles for a successful lab-to-clinic pivot include mapping the sequence of vital decisions that influence each other throughout the development process. For instance, the choice of primary packaging can affect material requirements and subsequently inform Quality by Design (QbD) strategies and regulatory documentation. By collaboratively outlining these decision sequences, drug owners can set a solid foundation for high-quality clinical batches. Additionally, formulation development should consider the practicalities of scaling up from the lab to Good Manufacturing Practice (GMP) environments. Early identification of product vulnerabilities and the selection of appropriate primary packaging formats, such as syringes instead of traditional vials, can streamline future production and enhance product quality. Furthermore, planning for operational realities, including the transfer of analytical methods and the time required for quality agreements, is crucial to maintaining project timelines. Ultimately, each transition from lab to clinic presents unique challenges that require careful consideration of modality, formulation complexity, and regulatory strategies. Engaging with experienced teams, such as those at Vetter, can provide valuable insights and guidance throughout this critical phase of drug development.

BioPharma Dive · Jun 15

Innovative Therapies for Celiac Disease: A New Era of Treatment Options

Celiac disease, affecting approximately 1 in 100 individuals globally, has long been managed solely through a strict gluten-free diet. This dietary restriction, while essential, does not fully protect patients from accidental gluten exposure, which can lead to significant gastrointestinal symptoms and intestinal damage. As awareness of the disease's complexities grows, the medical community is shifting its focus towards developing targeted therapies that address the underlying inflammatory mechanisms of celiac disease. First Tracks Biotherapeutics is at the forefront of this therapeutic innovation, working on ANB033, an investigational antibody that targets CD122, a key component in the inflammatory pathways associated with celiac disease. This approach aims to modulate immune responses that contribute to mucosal injury, potentially offering relief to patients who continue to suffer despite adhering to a gluten-free diet. Current research indicates that ANB033 may prevent gluten-induced damage in the digestive tract, marking a significant advancement in treatment options. The company is currently enrolling patients in a Phase 1b clinical trial designed to assess the efficacy of ANB033 in two distinct cohorts: one with mild mucosal disruption and another with more severe injury. This innovative trial design aims to provide clinically relevant data that reflects real-world patient needs, with results expected by late 2026. The study will prioritize both histological outcomes and patient-reported symptoms, utilizing the Celiac Disease Symptom Diary, which aligns with FDA guidelines. The potential introduction of effective therapies could revolutionize the management of celiac disease, shifting it from a condition primarily addressed through dietary counseling to one that can be actively treated by gastroenterologists. As the field evolves, the first successful therapy could redefine celiac disease as a serious medical condition with viable treatment options, significantly improving the quality of life for those affected.

BioPharma Dive · Jun 15

J&J's Talvey and Darzalex Faspro Show Promise in Early Multiple Myeloma Treatment

Johnson & Johnson's MonumenTAL-3 phase 3 clinical trial has demonstrated the efficacy of the bispecific antibody Talvey in combination with Darzalex Faspro for patients with earlier-stage multiple myeloma. This significant study has been selected for a plenary presentation at the upcoming 2026 European Hematology Association (EHA) annual meeting, highlighting its importance in advancing treatment options for this patient population. The findings from this trial could potentially reshape treatment protocols, offering new hope for patients diagnosed at an earlier stage of the disease. As multiple myeloma remains a challenging condition to manage, the results from this study may influence future clinical guidelines and therapeutic strategies, emphasizing the need for ongoing research in this area.

Fierce Pharma

FDA Hearing to Review Amgen's Tavneos Amid Independent Data Evaluation

Amgen is set to present findings regarding its rare disease treatment, Tavneos, at an upcoming FDA hearing. This hearing is critical as it may influence the drug's availability in the market. An independent research firm has been tasked with reviewing the data surrounding Tavneos, which is essential for assessing its efficacy and safety. The outcome of this review and the subsequent FDA hearing will have significant implications for patients relying on this treatment for their rare conditions. Stakeholders, including healthcare providers and patients, are closely monitoring the situation as it unfolds, given the potential impact on treatment options for rare diseases.

Fierce Pharma